{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:54:36Z","timestamp":1777290876975,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T00:00:00Z","timestamp":1392854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00774-014-0564-z","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T16:22:12Z","timestamp":1392826932000},"page":"601-604","source":"Crossref","is-referenced-by-count":16,"title":["A case of teriparatide-induced severe hypophosphatemia and hypercalcemia"],"prefix":"10.1007","volume":"32","author":[{"given":"Maiko","family":"Hajime","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,20]]},"reference":[{"key":"564_CR1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","volume":"29","author":"P Roschger","year":"2003","unstructured":"Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzi P, Klaushofter K (2003) Alendronate increases the degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185\u2013191","journal-title":"Bone"},{"key":"564_CR2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S8756-3282(01)00613-5","volume":"29","author":"C Hernandez","year":"2001","unstructured":"Hernandez C, Beaupre GS, Marcus R, Carter DR (2001) A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29:511\u2013516","journal-title":"Bone"},{"key":"564_CR3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00774-012-0365-1","volume":"30","author":"N Likuni","year":"2012","unstructured":"Likuni N, Hamaya E, Nihojima S, Yokoyama S, Goto W, Taketsuna M, Miyauchi A, Sowa H (2012) Safety and effectiveness profile of raloxifene in long-term, prospective postmarketing surveillance. J Bone Miner Metab 30:674\u2013682","journal-title":"J Bone Miner Metab"},{"key":"564_CR4","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI9038","volume":"105","author":"M Gowen","year":"2000","unstructured":"Gowen M, Stroup GB, Dodds RA (2000) Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595\u20131604","journal-title":"J Clin Invest"},{"key":"564_CR5","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(05)66782-7","volume":"365","author":"SJ Steddon","year":"2005","unstructured":"Steddon SJ, Cunningham J (2005) Calcimimetics and calcilytics fooling the calcium receptor. Lancet 365:2237\u20132239","journal-title":"Lancet"},{"key":"564_CR6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1359\/jbmr.080231","volume":"23","author":"P Chavassieux","year":"2008","unstructured":"Chavassieux P, Asser Karsdal M, Segovia-Silvestre T, Chapurlat R, Boivin G, Delmas PD (2008) Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 23:1076\u20131083","journal-title":"J Bone Miner Res"},{"key":"564_CR7","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"DW Dempster","year":"2001","unstructured":"Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846\u20131853","journal-title":"J Bone Miner Res"},{"key":"564_CR8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0149-2918(04)90128-2","volume":"26","author":"E Quattrocchi","year":"2004","unstructured":"Quattrocchi E, Kourlas H (2004) Teriparatide: a review. Clin Ther 26:841\u2013854","journal-title":"Clin Ther"},{"key":"564_CR9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ishi-shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"564_CR10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688\u2013733","journal-title":"Endocr Rev"},{"key":"564_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317","journal-title":"J Bone Miner Res"},{"key":"564_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00774-009-0123-1","volume":"28","author":"KM Ryder","year":"2010","unstructured":"Ryder KM, Tanner SB, Carbone L, Williams JE, Taylor HM, Bush A, Pintea V, Watsky MA (2010) Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals woth osteoporosis. J Bone Miner Metab 28:233\u2013239","journal-title":"J Bone Miner Metab"},{"key":"564_CR13","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1210\/jc.2006-2439","volume":"92","author":"PD Miller","year":"2007","unstructured":"Miller PD, Bilezilian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R (2007) Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 92:3535\u20133541","journal-title":"J Clin Endocrinol Metab"},{"key":"564_CR14","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216\u20131226","journal-title":"N Engl J Med"},{"key":"564_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/0253-7613.93869","volume":"44","author":"C Karatoprak","year":"2012","unstructured":"Karatoprak C, Kayatas K, Kilicaslan H, Yolbas S, Yazimci NA, Gumuskemer T, Demirtunc R (2012) Severe hypercalcemia due to teriparatide. Indian J Pharmacol 44:270\u2013271","journal-title":"Indian J Pharmacol"},{"key":"564_CR16","first-page":"142","volume":"2","author":"T Fujita","year":"1984","unstructured":"Fujita T, Baba H, Fukami T, Imai Y, Yoshimoto Y, Watanabe S, Katsuragi S, Takahara M (1984) Mechanism of degradation of N-terminal fragment of human parathyroid hormone (hPTH 1\u201334). Jpn J Bone Min Metab 2:142\u2013153","journal-title":"Jpn J Bone Min Metab"},{"key":"564_CR17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lpm.2010.09.028","volume":"40","author":"H EI Ouahabi","year":"2011","unstructured":"EI Ouahabi H, Do Cao C, Janicki E, Mulliez E, Ajdi F, Wemwau JL (2011) Hepatic and cutaneous affections induced by antithyroid drugs revealing haemochromatosis and porphyria cutanea tarda. Presse Med 40:319\u2013323","journal-title":"Presse Med"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-014-0564-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-014-0564-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-014-0564-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:16:53Z","timestamp":1559110613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-014-0564-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1007\/s00774-014-0564-z","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}